A company insider recently bought 12,000 shares of BridgeBio Pharma Inc. [BBIO]. Should You Buy?

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. BridgeBio Pharma Inc. shares valued at $100,680 were purchased by Ellis Andrea on Mar 15. At $8.39 per share, Ellis Andrea acquired 12,000 shares. The insider’s holdings grew to 12,000 shares worth approximately $0.12 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Also, Dachille Douglas A. purchased 10,000 shares, netting a total of over 81,934 in proceeds. Following the buying of shares at $8.19 each, the insider now holds 20,000 shares.

Before that, Dachille Douglas A. had added 5,000 shares to its account. In a trade valued at $79,550, the Director bought BridgeBio Pharma Inc. shares for $15.91 each. Upon closing the transaction, the insider’s holdings increased to 5,000 shares, worth approximately $99800.0.

As published in a research note from SVB Leerink on December 27, 2021, BridgeBio Pharma Inc. [BBIO] has been retained to an Outperform and the price target has been revised to $24. This represents a 58.42% premium over Thursday’s closing price. Analysts at Mizuho resumed the stock at ‘”a Buy”‘ outlook in a report released in late December. As of September 10, 2021, BofA Securities has increased its “Neutral” rating to a “Buy” for BBIO. Earlier on May 21, 2021, UBS initiated its rating. Their recommendation was “a Buy” for BBIO stock.

Analyzing BBIO’s Price Performance

On Thursday, BridgeBio Pharma Inc. [NASDAQ: BBIO] rose 25.69% to $9.98. The stock’s lowest price that day was $7.91, but it reached a high of $10.02 in the same session. During the last five days, there has been a surge of approximately 9.43%. Over the course of the year, BridgeBio Pharma Inc. shares have dropped approximately -40.17%. Shares of the company reached a 52-week high of $18.13 on 01/04/22 and a 52-week low of $4.98 on 05/12/22. A 50-day SMA is recorded $8.53, while a 200-day SMA reached $10.74. Nevertheless, trading volume fell to 5.6 million shares from 1.64 million shares the previous day.

Support And Resistance Levels for BridgeBio Pharma Inc. (BBIO)

According to the 24-hour chart, there is a support level at 8.59, which, if violated, would cause prices to drop to 7.19. In the upper region, resistance lies at 10.70. The next price resistance is at 11.41. RSI (Relative Strength Index) is 54.46 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.44, which suggests the price will decrease in the coming days. Percent R is at 36.60%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Is BridgeBio Pharma Inc. subject to short interest?

Stocks of BridgeBio Pharma Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by -0.12 million shares to 20.9 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 21.02 million shares. A decline of -0.57% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.01 of the overall float, the days-to-cover ratio (short ratio) decline to 10.01.

Which companies own the most shares of BridgeBio Pharma Inc. (BBIO)?

According to Viking Global Investors LP filings, the company currently owns 26,620,991 shares, which is about 18.02% of the total BBIO shares outstanding. The investor’s shares have plunged by 0 from its previous 13-F filing of 26620991.0 shares. With the completion of the buy transaction, SSgA Funds Management, Inc.’s stake is now worth $83,592,605. The Vanguard Group, Inc. acquire a 1.21% interest valued at $83.58 million while BlackRock Fund Advisors sold a -133,420 stake. A total of 0 shares of BridgeBio Pharma Inc. were sold by Aisling Capital Management LP during the quarter, and 0 were sold by HHLR Advisors Ltd. In its current portfolio, Perceptive Advisors LLC holds 3,839,380 shares valued at $34.86 million.

In terms of BridgeBio Pharma Inc. share price expectations, FactSet research, analysts set an average price target of $23.75 in the next 12 months, up nearly 195.97% from the previous closing price of $7.94. Analysts anticipate BridgeBio Pharma Inc. stock to reach $32.00 by 2022, with the lowest price target being $17.00. In spite of this, 8 analysts ranked BridgeBio Pharma Inc. stock as a Buy at the end of 2022. On March 22, 2021, Goldman assigned a price target of “a Buy” to the stock and reiterated coverage with a $91.


Please enter your comment!
Please enter your name here